To commemorate this momentous milestone.

Abramson Cancer Center of the University of Pennsylvania celebrates 40th anniversary This December marks the 40th anniversary of the Abramson Cancer Center of the University of Pennsylvania being designated a Comprehensive Cancer Middle by the National Tumor Institute. To commemorate this momentous milestone, over 400 people gathered together early this month for an event recognizing the center's vast achievements in malignancy research, individual care, and education over the last four years ed treatment .

Although significant advancements have been manufactured in the administration of vomiting, nausea remains a significant concern. We believe APD403 is an excellent anti-vomiting agent and a fantastic anti-nauseant, thereby having the potential to produce a significant contribution to cancer care.’ APD403 contains the marketed dopamine D2 /D3 antagonist amisulpride for the new currently, patent-protected, use of management of CINV. The active ingredient is also being developed as APD421 for preventing post-operative nausea & vomiting , with two pivotal Phase III clinical studies recently having been initiated..